Selecta Biosciences, Inc. (NASDAQ:SELB) Q2 2019 Earnings Conference Call Transcript
Aug 08, 2019 • 08:30 am ET
Good morning. Thank you for holding. Welcome to the Selecta Biosciences' Second Quarter Financial Results Conference Call.
For opening remarks, I'd now like to turn the call over to Elona Kogan. Please go ahead.
Thank you and good morning, everyone. Earlier today, we issued a press release containing our second quarter 2019 financial results and other corporate updates and we filed our 10-Q. This release and the 10-Q, can be accessed by visiting our website at www.selectabio.com.
I am joined today by Carsten Brunn, our CEO; and Stephen Smolinski, our CCO, and Dr. Kei Kishimoto, our Chief Scientific Officer, who will be available for the Q&A portion of the call.
Before we get started, we would like to advise that certain remarks that are made during this call, including without limitation, statements about the Company's future expectations, plans and prospects, the potential of our ImmTOR platform, the anticipated timing of planned trials, related data readouts and ability of results to inform future trials, our collaboration with AskBio, our collaboration with CureCN, a development and market potential for our products, the sufficiency of the Company's cash, cash equivalents and short-term investments constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by these forward-looking statements, as a result of various important factors, including those discussed in the Risk Factors section of Selecta's most recent quarterly report on Form 10-Q filed with the SEC, which can be accessed at selectabio.com.
In addition, any forward-looking statements, represent the Company's views only as of today, August 8th, 2019, and should not be relied upon as representing the Company's views as of any subsequent date. While Selecta may elect to update these forward-looking statements at some point in the future, it specifically disclaims any intention to do so, even if management's views change.
And now let me introduce Carsten Brunn, who will kick things-off today.
Thank you, Elona. And good morning, everyone. This quarter, we continued to gain traction and momentum for immune tolerance platform, ImmTOR, and we are particularly excited about its potential in therapeutic biologics, enzymes and AAV gene therapy. The current challenge for drug development in these areas is the limitations caused by the body's own immune response.
Many biologic therapies when administered, will trigger the immune system to develop neutralizing antibodies that counteract their therapeutic benefit. Our answer to this challenge is our ImmTOR platform, which promotes selective immune tolerance of the therapy, allowing the therapeutic goal to be achieved.
For our lead development program, SEL-212, for the treatment of Chronic Refractory Gout, we've made good progress and patient enrollment is progressing in our six months head-to-head COMPARE trial, designed to evaluate SEL-212 compared to Krystexxa in adult patients with Chronic Refractory Gout. If successful, this trial will give us an opportunity to demonstrate the superiority of SEL-212. Stephen will talk in more detail about this program in a moment.
We are extremely